Regenerative therapy with mesenchymal stem cells at the site of malignant primary bone tumour resection: what are the risks of early or late local recurrence?
The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
Purpose There is concern that regenerative cell-based therapies at the site of malignant primary bone tumours could result in increased risk of local tumour recurrence. We therefore investigated the long-term risks for site-specific recurrences in patients who had received an autologous bone marrow derived mesenchymal stem cell suspension to improve healing at the host-to-allograft bone junction of the reconstruction after bone tumour resection. Methods A total of 92 patients were treated from 1993 to 2003 with bone marrow-derived mesenchymal stem cells after bone tumour resection. Patients were monitored for cancer incidence from the date of first operation (1993) until death, or until 31 December 2013. The mean follow-up time was 15.4 years (range ten to 20 years). The average number of MSCs returned to the patient was 234,000 MSCs ± 215,000. The primary outcome was to evaluate the risk of tumorigenesis recurrence at the cell therapy treatment sites with radiographs and/or MRIs. The relative risk of cancer recurrence was expressed as the ratio of observed and expected number of cases according to three different control populations. Results Thirteen recurrences were found at the treatment sites among the 92 patients. The expected number of recurrences based on incidence in the three cohort populations was between 15 and 20 for the same cancer, age and sex distribution. The standardized incidence ratio (equal to observed cancers divided by expected cancers) for the entire fo…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is preliminary clinical evidence for mesenchymal stromal cell in promoting bone regeneration within large bone defects after surgical excision.”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [100]
In the citing paper
“They found no increase in the risk of local recurrence for all cancer types [100].”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [100]
In the citing paper
“Using three control groups, they concluded that the use of MSCs is probably safe, demonstrating no increase in the risk of local recurrence for all cancer types [100].”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [100]
Citations
Cites
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393 · cited 1×
“6 % that appears to conform to the other series in the literature [2, 3, 14, 15, 17, 28, 29, 39] for the main tumours (osteosarcoma, chondrosarcoma, and Ewing sarcoma).”
Lalu, M. M., McIntyre, L., Pugliese, C., Fergusson, D., Winston, B. W., Marshall, J. C., Granton, J., Stewart, D. J., & Canadian Critical Care Trials Group (2012) · PLoS ONE · doi:10.1371/journal.pone.0047559 · Cited by 1,146 · cited 1×
“Many experimental studies [7, 12, 27, 31, 33, 35, 52] in vitro and in animals have been performed to identify the MSC mediators acting on bone tumours cells.”
BackgroundCarcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells
Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., Ganesan, S., Glod, J. W., & Banerjee, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0943 · Cited by 912 · cited 1×
“Controversial results have been reported when MSCs have been injected into mice with induced tumour, resulting either in promotion or inhibition of tumour growth depending on the studies [40, 42].”
BackgroundStudeny, M., Marini, F. C., Dembinski, J. L., Zompetta, C., Cabreira-Hansen, M., Bekele, B. N., Champlin, R. E., & Andreeff, M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh299 · Cited by 842
Review: Mesenchymal Stem Cells: Cell–Based Reconstructive Therapy in Orthopedics
Caplan, A. I. (2005) · Tissue Engineering · doi:10.1089/ten.2005.11.1198 · Cited by 822
Hernigou, P. (2005) · The Journal of Bone and Joint Surgery (American) · doi:10.2106/jbjs.d.02215 · Cited by 787 · cited 2×
“The bone marrow aspirate was transferred immediately [22] to the processing laboratory, where the nucleated cells (including progenitor cells) were isolated by using a cell separator (Cobe 2991; Gambo BCT, Paris, France).”
BackgroundMethodSelf-citationFat Grafting to the Breast Revisited: Safety and Efficacy
Coleman, S. R., & Saboeiro, A. P. (2007) · Plastic and Reconstructive Surgery · doi:10.1097/01.prs.0000252001.59162.c9 · Cited by 724
Robison, L. L., Armstrong, G. T., Boice, J. D., Chow, E. J., Davies, S. M., Donaldson, S. S., Green, D. M., Hammond, S., Meadows, A. T., Mertens, A. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3339 · Cited by 669
Sarcoma Derived from Cultured Mesenchymal Stem Cells
Tolar, J., Nauta, A. J., Osborn, M. J., Panoskaltsis Mortari, A., McElmurry, R. T., Bell, S., Xia, L., Zhou, N., Riddle, M., Schroeder, T. M., et al. (2007) · Stem Cells · doi:10.1634/stemcells.2005-0620 · Cited by 639 · cited 2×
“During this period there was no discussion as there is today about relationship between bone tumours and MSCs [16, 47] and particularly that MSCs might be the progenitors of Ewing sarcoma [1].”
BackgroundResultAntitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model
Nakamura, K., Ito, Y., Kawano, Y., Kurozumi, K., Kobune, M., Tsuda, H., Bizen, A., Honmou, O., Niitsu, Y., & Hamada, H. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302276 · Cited by 597 · cited 1×
“Controversial results have been reported when MSCs have been injected into mice with induced tumour, resulting either in promotion or inhibition of tumour growth depending on the studies [40, 42].”
Background
Research works printed but not linked: 2
- Delepine G, Delepine N, Hernigou P (1991) Allograft with patellar tendon in reconstructive procedures after upper tibial resection. Limb Salvage Ed., Springer, pp 436–437
- Hernigou P, Beaujean F (1997) Autologous bone marrow to stimulate bone healing. J Cell Eng 2(3):113–116
Cited by
Stem Cell Therapy for the Treatment of Hip Osteonecrosis: A 30-Year Review of Progress
Hernigou, P., Trousselier, M., Roubineau, F., Bouthors, C., Chevallier, N., Rouard, H., & Flouzat–Lachaniette, C.-H. (2016) · Clinics in Orthopedic Surgery · doi:10.4055/cios.2016.8.1.1 · Cited by 147
Self-citationPerforming a Better Bone Marrow Aspiration
Friedlis, M. F., & Centeno, C. J. (2016) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2016.06.009 · Cited by 42
Avril, P., Le Nail, L.-R., Brennan, M. Á., Rosset, P., De Pinieux, G., Layrolle, P., Heymann, D., Perrot, P., & Trichet, V. (2016) · Journal of Bone Oncology · doi:10.1016/j.jbo.2015.11.002 · Cited by 38
“reported that the autologous concentrated bone marrow cell adjuvant therapy in 92 patients treated after bone tumor resection did not increase the risk of local tumor recurrence compared to control populations [63].”
BackgroundNew Advances in Stem Cell Therapy for Osteonecrosis of the Femoral Head
Zhou, W. J., Ming, Q., Lv, Y., & Zhu, J. (2019) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x13666181025120252 · Cited by 38
Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice
Stamatopoulos, A., Stamatopoulos, T., Gamie, Z., Kenanidis, E., Ribeiro, R. D. C., Rankin, K. S., Gerrand, C., Dalgarno, K., & Tsiridis, E. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2019.100231 · Cited by 37
Metadata
- Authors
- Hernigou, P., Flouzat Lachaniette, C. H., Delambre, J., Chevallier, N., & Rouard, H.
- Affiliations
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Corresponding author
- Hernigou, Philippe
- Venue
- International Orthopaedics
- Published
- 2014-06-07
- Volume
- 38
- Issue
- 9
- Pages
- 1825-1835
- ISSN
- 0341-2695 (ISSN-L)
- 1432-5195
- OpenAlex
- W1965962463
- Cited by
- 22
- References
- 52
- Citations by year
- 2024: 1 · 2023: 2 · 2021: 3 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 4 · 2015: 5 · 2014: 1
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- International Orthopaedics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Keywords
- mesenchymal stem cells, bone tumor resection, local recurrence, carcinogenesis, autologous cell therapy, bone marrow-derived stem cells, bone reconstruction, cancer risk, long-term follow-up, standardized incidence ratio
- MeSH terms
- Adolescent, Adult, Bone Neoplasms, Bone Regeneration, Child, Female, Follow-Up Studies, Humans, Magnetic Resonance Imaging, Male, Neoplasm Recurrence, Local, Retrospective Studies, Risk Factors, Time Factors, Incidence, Bone Transplantation, Treatment Outcome, Mesenchymal Stem Cell Transplantation, Young Adult, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Regenerative therapy with mesenchymal stem cells at the site of malignant primary bone tumour resection: what are the risks of early or late local recurrence? https://app.cochat.ai/papers/10.1007/s00264-014-2384-0
- The paper
- Hernigou, P., Flouzat Lachaniette, C. H., Delambre, J., Chevallier, N., & Rouard, H. (2014). Regenerative therapy with mesenchymal stem cells at the site of malignant primary bone tumour resection: what are the risks of early or late local recurrence? International Orthopaedics. https://doi.org/10.1007/s00264-014-2384-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.